+

WO2002004598A2 - Amelioration de performances de culture cellulaire - Google Patents

Amelioration de performances de culture cellulaire Download PDF

Info

Publication number
WO2002004598A2
WO2002004598A2 PCT/US2001/021864 US0121864W WO0204598A2 WO 2002004598 A2 WO2002004598 A2 WO 2002004598A2 US 0121864 W US0121864 W US 0121864W WO 0204598 A2 WO0204598 A2 WO 0204598A2
Authority
WO
WIPO (PCT)
Prior art keywords
dichloroacetate
culture medium
tissue culture
pyruvate dehydrogenase
dehydrogenase kinase
Prior art date
Application number
PCT/US2001/021864
Other languages
English (en)
Other versions
WO2002004598A3 (fr
Inventor
Brian D. Follstad
Original Assignee
Immunex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corporation filed Critical Immunex Corporation
Priority to AU2001275897A priority Critical patent/AU2001275897A1/en
Publication of WO2002004598A2 publication Critical patent/WO2002004598A2/fr
Publication of WO2002004598A3 publication Critical patent/WO2002004598A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Definitions

  • This invention is in the general field of animal cell culture. More particularly, the invention concerns improved medium and methods for the cultivation of animal cell lines and the production of natural and recombinant products derived therefrom.
  • lactic acidosis can be caused by inherited or spontaneously acquired mutations in genes encoding enzymes of mitochondrial glucose metabolism or oxidative phosphorylation.
  • glucose is broken down into pyruvate, which in turn is metabolized in the mitochondria to carbon dioxide and water via the tri-carboxylic acid (TCA) cycle.
  • TCA tri-carboxylic acid
  • pyruvate is instead shunted into anaerobic glycolysis and converted into lactic acid or lactate.
  • Dichloroacetate has been used for many years as a drug in humans to treat conditions associated with lactic acidosis as well as diabetes and hyperlipoproteinemia (reviewed in Stacpoole et al, 1998, Drag. Metabol. Rev. 30(3):499-539; see also US Patents Nos. 4,122,188 to Stacpoole, 4,631,294 to Barsan, and 5,587,397 to Fox).
  • Dichloroacetate inhibits Pyruvate Dehydrogenase (PDH) kinase activity, which in turn leads to the activation of the PDH complex and the redirection of pyruvate away from lactate formation and into the TCA cycle (Crabb et al, 1981, Metabolism 30(10): 1024-1039).
  • PDH Pyruvate Dehydrogenase
  • dichloroacetate is toxic to humans and other animals when administered at high or chronic doses.
  • lactate accumulates in mammalian cell cultures, leading to acidification of the medium and inhibition of cell growth.
  • base is added in order to circumvent (at least in part) this problem.
  • chemical inhibitors of pyruvate dehydrogenase kinase are added to medium used for culturing animal cells in vitro.
  • Animal cell cultures grown in such medium demonstrated significantly reduced production of lactate. Consequently, the pH shifts that typically accompany cultured cell growth were reduced in non-pH controlled cell cultures, and less base addition was required in pH controlled cell cultures. Thus, culture robustness and performance was improved.
  • the invention provides a method for culturing animal cells in vitro, the method comprising culturing the animal cells in tissue culture medium containing an effective amount of an inhibitor of pyruvate dehydrogenase kinase.
  • Preferred cells are mammalian cells, and particularly CHO cells.
  • the inhibitor of pyruvate dehydrogenase kinase can be, for example, dichloroacetate or related salts of dichloroacetetic acid.
  • the inhibitor of pyruvate dehydrogenase kinase can be (R)-3, 3, 3-trifluoro-2-hydroxy-2- methylpropionic acid, or an anilide or amide derivative thereof.
  • the invention finds particular use in the culturing of animal cells that are genetically engineered to express a protein of interest.
  • the invention also provides a tissue culture medium containing an effective amount of an inhibitor of pyruvate dehydrogenase kinase.
  • FIG. 1 Viable cell concentration (solid lines) and percent cell viability (broken lines) measured as a function of time in culture. CHO cells were grown in shake flasks containing medium supplemented with the indicated concentration of dichloroacetate.
  • FIG. 1 Lactate accumulation (solid lines) and culture pH (broken lines) measured as a function of time in culture. CHO cells were grown in shake flasks containing medium supplemented with the indicated concentration of dichloroacetate.
  • Figure 3. Viable cell concentration (solid lines) and percent cell viability (broken lines) measured as a function of time in culture. CHO cells were grown in bioreactors containing medium supplemented with the indicated concentration of dichloroacetate.
  • FIG. 1 Lactate accumulation (solid lines) and sodium carbonate base added (broken lines) measured as a function of time in culture.
  • CHO cells were grown in bioreactors containing medium supplemented with the indicated concentration of dichloroacetate.
  • the invention is based, in part, on the discovery that inhibitors of pyruvate dehydrogenase kinase can be used in vitro to improve the performance and growth of animal cell cultures. Specifically, inhibitors of pyruvate dehydrogenase kinase act to reduce lactate formation in production cell culture, thereby enhancing culture robustness.
  • dichloroacetate was used as a model compound to inhibit pyruvate dehydrogenase kinase activity in a mammalian cell culture system.
  • a non-pH controlled culture system shake flasks
  • the reduction in lactate formation significantly reduced the pH shifts that accompanied cell growth which in turn led to a dramatic increase in the viable cell concentration and viability, hi a pH-controlled bioreactor, the lactate levels were again lower in the culture containing dichloroacetate but without a corresponding increase in the viable cell concentration.
  • the amount of base required to maintain the pH set-point was noticeably reduced.
  • the invention can improve the culture performance of generally any type of animal cell that can be grown in in vitro culture including but not limited to mammalian cells, insect cells, avian cells and reptilian cells.
  • animal cell is meant a cell whose progenitors were derived from a multicellular animal.
  • the animal cell lines are mammalian cell lines.
  • the invention is particularly advantageous for growing industrially important mammalian cell lines that have been adapted to grow in long term culture.
  • a wide variety of animal cell lines suitable for growth in culture are available from, for example, the American Type Culture Collection (ATCC, Manassas, VA) and NRRL (Peoria, IL). Some of the more established cell lines typically used in the industrial or academic laboratory and which are preferred are CHO, VERO, BHK, HeLa, Cos, CVl, MDCK, 293, 3T3, PC12, hybridoma, myeloma, and WI38 cell lines, to name but a few examples.
  • ATCC American Type Culture Collection
  • VA Manassas, VA
  • NRRL Peoria, IL
  • Some of the more established cell lines typically used in the industrial or academic laboratory and which are preferred are CHO, VERO, BHK, HeLa, Cos, CVl, MDCK, 293, 3T3, PC12, hybridoma, myeloma, and WI38 cell lines, to name but a few examples.
  • the dihydrofolate reductase (DHFR)-deficient mutant cell line (Urlaub et al, 1980, Proc Natl Acad Sci USA 77:4216-4220), DXB 11 and DG-44, are the CHO host cell lines of choice because the efficient DHFR selectable and amplifiable gene expression system allows high level recombinant protein expression in these cells (Kaufman R.J., 1990, Meth Enzymol 185:527-566). In addition, these cells are easy to manipulate as adherent or suspension cultures and exhibit relatively good genetic stability. In addition, new animal cell lines can be established using methods well known by those skilled in the art (e.g., by transformation, viral infection, and/or selection, etc.).
  • in vitro cell culture By in vitro cell culture is meant the growth and propagation of cells outside of a multicellular organism or tissue.
  • in vitro cell culture excludes the in vitro culturing of tissues isolated from an organism (e.g., a perfused heart tissue).
  • tissue culture plates e.g., 10 cm plates, 96 well plates, etc.
  • roller bottles or other adherent culture e.g.. , on microcarrier beads
  • Cultures can be grown in shake flasks, small scale bioreactors, and/or large scale bioreactors.
  • a bioreactor is a device used to culture animal cells in which environmental conditions such as temperature, atmosphere, agitation, and/or pH can be monitored and adjusted.
  • environmental conditions such as temperature, atmosphere, agitation, and/or pH can be monitored and adjusted.
  • a number of companies e.g., ABS Inc., Wilmington, DE; Cell Trends, Inc., Middletown, MD
  • university and/or government- sponsored organizations e.g., The Cell Culture Center, Minneapolis, MN offer cell culture services on a contract basis.
  • Animal cell cultures can be cultured in small to large scale processes, hi small, non-pH controlled processes (where pH is controlled by the initial buffer components in the medium, and not adjusted during the culture process except by the changing of the medium), the invention finds particular use because it reduces pH shifts due to lactate production. Hence, the cell cultures have increased levels of viable cell concentration and percent viability. In pH controlled processes (e.g., bioreactors), where the pH is continually adjusted, less base components are necessary over the life of the culture. Therefore, the invention provides a number of advantages regardless of the size or type of cell culture used.
  • Tissue culture medium is defined, for purposes of the invention, as a medium suitable for growth of animal cells, and preferably mammalian cells, in in vitro cell culture.
  • tissue culture medium contains a buffer, salts, energy source, amino acids, vitamins and trace essential elements.
  • the medium can oftentimes require additional components such as growth factors, lipids, and/or other serum components (e.g., transferrin).
  • Any media capable of supporting growth of animal cells in culture can be used; the invention is broadly applicable to animal cells in culture, particularly mammalian cells, and the choice of media is not crucial to the invention.
  • Tissue culture media suitable for use in the invention are commercially available from ATCC (Manassas, VA). For example, any one or combination of the following media can be used: RPMI-1640 Medium, Dulbecco's Modified Eagle's Medium, Minimum Essential Medium Eagle, F-12K Medium, Iscove's Modified
  • Dulbecco's Medium Often, depending upon the requirements of the particular cell line used, media also contains a serum additive such as Fetal Bovine Serum, or a serum replacement.
  • a serum additive such as Fetal Bovine Serum, or a serum replacement.
  • serum-replacments for serum-free growth of cells
  • TCHTM, TM-235TM, and TCHTM these products are available commercially from Celox (St. Paul, MN).
  • Celox St. Paul, MN
  • the medium is usually highly enriched for amino acids and trace elements (see, for example, U.S. Patent No. 5,122,469 to Mather et al., and U.S. Patent No. 5,633,162 to Keen et al).
  • an effective amount of an inhibitor of pyruvate dehydrogenase kinase is that amount sufficient to reduce lactate formation by at least 10%, and preferably 20%, over 48 hours in culture.
  • An inhibitor of pyruvate dehydrogenase kinase is defined as an organic molecule that prevents PDH kinase from phosphorylating the specific serine residues on the El (alpha subunit) of the PDH complex involved in regulating PDH activity.
  • an inhibitor of pyruvate dehydrogenase kinase for purposes of the invention are non-specific inhibitory conditions such as alterations in ionic strength and/or phosphate concentrations, and non-specific kinase and/or enzymatic inactivating agents such as DEPC. Also excluded from the definition of an inhibitor of pyruvate dehydrogenase kinase for purposes of the invention is pyruvate, since addition of pyruvate also increases the undesired production of lactate.
  • X is any mono or divalent metallic cation
  • a is an integer from 1 to 2 inclusive
  • b is an integer from 1 to 2 inclusive.
  • Specific salts include those formed by the alkali metal and alkaline earth metal ions such as sodium, potassium, calcium, and magnesium, ammonium, and substituted ammonium where the substituent is a mono- or di-lower alkyl radical of 1-4 carbon atoms and ethylene di- ammonium.
  • Pharmaceutically acceptable salts with minimum cell cytotoxicity, are preferred.
  • Specific pharmaceutical salts useful in this invention include sodium dichloroacetate, potassium dichloroacetate, and diisoproyl ammonium dichloroacetate.
  • the sodium dichloroacetate and free base forms are highly preferred. Generally, salt and free base forms of dichloroacetate are particularly preferred for use in the invention because of their ready availability and economical price.
  • Salts of dichloroacetic acid can be used at a concentration between about 0.5 mM to about 100 mM, preferably about 50 mM. Preferably such compounds are used at a concentration of at least about 1 mM, more preferably at least about 4 mM, and most preferably at about 10 mM.
  • the invention also includes the use of other specific inhibitors of pyruvate dehydrogenase kinase that are known or yet to be discovered. For example, difluoroacetate, 2-chloroproprionate, 3- chloroproprionate, and 2,2' -dichloroacetate are inhibitors (Crabb et al, 1981, cited above).
  • (R)-trifluoro-2-hydroxy-2-methylpropionic acid is a mild inhibitor. Bebemitz et al. , 2000, J. Med. Chem. 43(ll):2248-57, describes a series of anilides of (R)-trifluoro-2-hydroxy-2- methylpropionic acid that act as improved inhibitors of pyruvate dehydrogenase kinase. These include N-phenyl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide 1, and derivatives substituted at the ortho position with a small electron-withdrawing group, such as, for example, chloro, acetyl, or bromo.
  • a particularly preferred compound is N-(2-Chloro-4-isobutylsulfamoylphenyl)- (R)-3, 3, 3-trifluoro-2-hydroxy-2-methylpropionamide. Further, Aicher et al, 2000, J. Med. Chem. 43(2):236-249, describe a series of secondary amides that are also derived from (R)- trifluoro-2-hydroxy-2-methylpropionic acid.
  • concentration of such compounds to use in the invention can be determined by those skilled in the art by, for example, comparing the inhibitory activity against pyruvate dehydrogenase kinase of the compound to that of dichloroacetate, and extrapolating appropriate concentrations therefrom. The extrapolated concentrations can then be used as a starting point to determine the range of effective amounts of compound that should be added to a culture medium, which amounts can then be determined using small scale experiments such as those described herein.
  • the invention finds particular utility in improving the production of proteins via cell culture processes.
  • the cell lines used in the invention can be genetically engineered to express a protein of commercial or scientific interest.
  • genetically engineered is meant that the cell line has been transfected, transformed or transduced with a recombinant polynucleotide molecule, and/or otherwise altered (e.g., by homologous recombination and gene activation) so as to cause the cell to express a desired protein.
  • Methods and vectors for genetically engineering cells and/or cell lines to express a protein of interest are well known to those of skill in the art; for example, various techniques are illustrated in Current Protocols in Molecular Biology. Ausubel et al, eds. (Wiley & Sons, New York, 1988, and quarterly updates) and Sambrook et al, Molecular Cloning: A Laboratory Manual (Cold Spring Laboratory Press, 1989).
  • proteins for expression are protein-based drugs, also known as biologies.
  • the proteins are expressed as extracellular products.
  • Proteins that can be produced using the invention include but are not limited to Flt3 ligand, CD40 ligand, erythropoeitin, thrombopoeitin, calcitonin, Fas ligand, ligand for receptor activator of NF-kappa B (RANKL), TNF-related apoptosis-inducing ligand (TRAIL), ORK/Tek, thymic stroma-derived lymphopoietin, granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor, mast cell growth factor, stem cell growth factor, epidermal growth factor, RANTES, growth hormone, insulin, insulinotropin, insulin-like growtii factors, parathyroid hormone, interferons, nerve growth factors, glucagon, interleukins 1 through 18, colony stimulating factors, lymphotoxin- ⁇
  • proteins that can be produced according to the invention may be found in, for example, Human Cvtokines: Handbook for Basic and Clinical Research. Vol. II (Aggarwal and Gutterman, eds. Blackwell Sciences, Cambridge MA, 1998); Growth Factors:A Practical Approach (McKay and Leigh, eds., Oxford University Press Inc., New York, 1993) and The Cvtokine Handbook (AW Thompson, ed.; Academic Press, San Diego CA; 1991).
  • the receptors for any of the aforementioned proteins can also be improved using the invention, including the receptors for both forms of tumor necrosis factor receptor (referred to as p55 and p75), Interleukin-1 receptors (type 1 and 2), rnterleukin-4 receptor, rnterleukin-15 receptor, Interleukin-17 receptor, Interleukin-18 receptor, granulocyte-macrophage colony stimulating factor receptor, granulocyte colony stimulating factor receptor, receptors for oncostatin-M and leukemia inhibitory factor, receptor activator of NF-kappa B (RANK), receptors for TRAIL, and receptors that comprise death domains, such as Fas or Apoptosis-Inducing Receptor (AIR).
  • a particularly preferred receptor is a soluble form of the B -l receptor type II; such proteins are described in US Patent No. 5,767,064, incorporated herein by reference in its entirety.
  • CD proteins cluster of differentiation antigens
  • CD proteins include cluster of differentiation antigens (referred to as CD proteins), for example, those disclosed in Leukocyte Typing VI (Proceedings of the Vlth International Workshop and Conference; Kishimoto, Kikutani et al., eds.; Kobe, Japan, 1996), or CD molecules disclosed in subsequent workshops.
  • CD proteins include CD27, CD30, CD39, CD40; and ligands thereto (CD27 ligand, CD30 ligand and CD40 ligand).
  • TNF receptor family which also includes 4 IBB and OX40
  • the ligands are often members of the TNF family (as are 4 IBB ligand and OX40 ligand); accordingly, members of the TNF and TNFR families can also be produced using the present invention.
  • Proteins that are enzymatically active can also be produced according to the instant invention.
  • Examples include metalloproteinase-disintegrin family members, various kinases, glucocerebrosidase, alpha-galactosidase A, superoxide dismutase, tissue plasminogen activator, Factor VJJJ, Factor LX, apolipoprotein E, apolipoprotein A-I, globins, an IL-2 antagonist, alpha- 1 antitrypsin, TNF-alpha Converting Enzyme, and numerous other enzymes.
  • Ligands for enzymatically active proteins can also be produced by applying the instant invention.
  • compositions and methods are also useful for production of other types of recombinant proteins, including immunoglobulin molecules or portions thereof, and chimeric antibodies (i.e., an antibody having a human constant region couples to a murine antigen binding region) or fragments thereof.
  • chimeric antibodies i.e., an antibody having a human constant region couples to a murine antigen binding region
  • DNA encoding immunoglobulin molecules can be manipulated to yield DNAs capable of encoding recombinant proteins such as single chain antibodies, antibodies with enhanced affinity, or other antibody- based polypeptides (see, for example, Larrick et al., 1989, Biotechnology 7:934-938; Reichmann et al, 1988, Nature 332:323-327; Roberts et al, 1987, Nature 328:731-734; Verhoeyen et al, 1988, Science 239:1534-1536; Chaudhary et al, 1989, Nature 339:394-397).
  • humanized antibody also encompasses single chain antibodies. See, e.g., Cabilly et al, U.S. Pat. No. 4,816,567; Cabilly et al, European Patent No. 0,125,023 Bl; Boss et al, U.S. Pat. No. 4,816,397; Boss et al, European Patent No. 0,120,694 Bl; Neuberger, M. S. et al, WO 86/01533; Neuberger, M. S. et al, European Patent No. 0,194,276 Bl; Winter, U.S. Pat. No. 5,225,539;
  • the invention can be used to induce the expression of human and/or humanized antibodies that immunospecifically recognize specific cellular targets, e.g., any of the aforementioned proteins, the human EGF receptor, the her-2/neu antigen, the CEA antigen, Prostate Specific Membrane Antigen (PSMA), CD5, CDlla, CD18, NGF, CD20, CD45, Ep-cam, other cancer cell surface molecules, TNF-alpha, TGF-bl, VEGF, other cytokines, alpha 4 beta 7 integrin, IgEs, viral proteins (for example, cytomegalovirus), etc., to name just a few.
  • specific cellular targets e.g., any of the aforementioned proteins, the human EGF receptor, the her-2/neu antigen, the CEA antigen, Prostate Specific Membrane Antigen (PSMA), CD5, CDlla, CD18, NGF, CD20, CD45, Ep-cam, other cancer cell surface molecules, TNF-alpha, TGF-bl, VE
  • a fusion protein is a protein, or domain or a protein (e.g. a soluble extracellular domain) fused to a heterologous protein or peptide.
  • fusion proteins include proteins expressed as a fusion with a portion of an immunoglobulin molecule, proteins expressed as fusion proteins with a zipper moiety, and novel polyfunctional proteins such as a fusion proteins of a cytokine and a growth factor (i.e., GM-CSF and IL-3, MGF and IL-3).
  • WO 93/08207 and WO 96/40918 describe the preparation of various soluble oligomeric forms of a molecule referred to as CD40L, including an immunoglobulin fusion protein and a zipper fusion protein, respectively; the techniques discussed therein are applicable to other proteins.
  • Another fusion protein is a recombinant TNFR:Fc, also known as "entanercept.” Entanercept is a dimer of two molecules of the extracellular portion of the p75 TNF alpha receptor, each molecule consisting of a 235 amino acid TNFR-derived polypeptide that is fused to a 232 amino acid Fc portion of human IgGl.
  • any of the previously described molecules can be expressed as a fusion protein including but not limited to the extracellular domain of a cellular receptor molecule, an enzyme, a hormone, a cytokine, a portion of an immunoglobulin molecule, a zipper domain, and an epitope.
  • the resulting expressed protein can then be collected.
  • the protein can purified, or partially purified, from such culture or component (e.g., from culture medium or cell extracts or bodily fluid) using known processes.
  • partially purified means that some fractionation procedure, or procedures, have been carried out, but that more polypeptide species (at least 10%) than the desired protein is present.
  • purified is meant that the protein is essentially homogeneous, i.e., less than 1% contaminating proteins are present.
  • Fractionation procedures can include but are not limited to one or more steps of filtration, centrifugation, precipitation, phase separation, affinity purification, gel filtration, ion exchange chromatography, hydrophobic interaction chromatography (HJ.C; using such resins as phenyl ether, butyl ether, or propyl ether), HPLC, or some combination of above.
  • the invention also optionally encompasses further formulating the proteins.
  • formulating is meant that the proteins can be buffer exchanged, sterilized, bulk-packaged and or packaged for a final user.
  • sterile bulk form means that a formulation is free, or essentially free, of microbial contamination (to such an extent as is acceptable for food and/or drug purposes), and is of defined composition and concentration.
  • sterile unit dose form means a form that is appropriate for the customer and/or patient administration or consumption.
  • Such compositions can comprise an effective amount of the protein, in combination with other components such as a physiologically acceptable diluent, carrier, or excipient.
  • physiologically acceptable means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s).
  • Shake flasks were inoculated at 5.0xl0 5 cells/ml with either 0, 0.5, 5.0, or 10.0 mM of dichloroacetate (Cat.# 157638, ICN Biomedicals, Inc., Costa Mesa, CA). The dichloroacetate was added to the medium and pH adjusted with NaOH before adding the cells. Shake flasks were maintained in an incubator set at 37°C on a shake flask platform set at 150 rpm. Measurements for cell concentration and viability were taken using a hemacytometer and the trypan blue dye exclusion method. Glucose and lactate levels were determined using a 2700 Select YSI analyzer (Yellow Springs, OH). pC0 2 , p0 2 , and pH were determined using a blood gas analyzer (Chiron, Emeryville, CA).
  • Viable cell concentration and viability values for the cultures are shown in Figure 1.
  • the higher dichloroacetate concentrations resulted in increasing viable cell concentrations and viabilities.
  • the most dramatic results were observed using 10.0 mM dichloroacetate in the culture, in which the viable cell concentration was almost twice that of the control with a significantly higher viability.
  • This difference in culture viable cell concentration and viability could be explained by measuring both the culture lactate levels and pH.
  • the measured lactate concentrations and pH correlated directly with the dichloroacetate levels as shown in Figure 2.
  • 10.0 mM dichloroacetate resulted in an almost one-third drop in the culture lactate levels and an almost 0.3 pH unit difference compared to the control.
  • the bioreactor experiments were performed using 2.0 L reactors with a 1.0 L working volume (Applikon, Foster City, CA).
  • a DCU controller B. Braun Biotech International, AUentown, PA
  • Oxygen was supplied through headspace aeration and sparging.
  • Reactor inoculum was obtained from spinner flask cultures grown under conditions identical to those described above for the shake flask cultures. Dichloroacetate was added to the medium and pH adjusted with NaOH before adding the cells.
  • Reactors were inoculated at 5.0xl0 5 cells/1 with a viability greater than 94%. The cell concentration, viability, glucose, lactate, pC0 2 , p0 2 , and pH were measured as described above.
  • the culture viable cell concentrations and viabilities did not differ noticeably for the control and dichloroacetate containing cultures as shown in Figure 3.
  • the lactate levels and the amount of sodium carbonate base added to adjust the culture pH did differ as shown in Figure 4.
  • the culture with dichloroacetate had a lower amount of lactate and a corresponding reduction in the amount of base required to neutralize this acid.
  • the ⁇ C0 2 levels increased faster in the culture containing dichloroacetate versus the control.
  • the additional acidity caused by rising pC0 2 levels caused the base addition requirement to increase at that point. Using more effective methods to eliminate the accumulation of dissolved C0 2 in the dichloroacetate culture would most likely result in further reduction in the amount of base required.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne des procédés et des compositions servant à améliorer la culture in vitro de cellules animales et mettant en application des inhibiteurs de pyruvate déshydrogénase kinase. Les inhibiteurs particulièrement préférés consistent en des sels d'acide dichloroacétique, tels que dichloroacétate de sodium.
PCT/US2001/021864 2000-07-12 2001-07-10 Amelioration de performances de culture cellulaire WO2002004598A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001275897A AU2001275897A1 (en) 2000-07-12 2001-07-10 Improvement of cell culture performance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21788900P 2000-07-12 2000-07-12
US60/217,889 2000-07-12

Publications (2)

Publication Number Publication Date
WO2002004598A2 true WO2002004598A2 (fr) 2002-01-17
WO2002004598A3 WO2002004598A3 (fr) 2002-04-04

Family

ID=22812901

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021864 WO2002004598A2 (fr) 2000-07-12 2001-07-10 Amelioration de performances de culture cellulaire

Country Status (2)

Country Link
AU (1) AU2001275897A1 (fr)
WO (1) WO2002004598A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006079155A1 (fr) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Molecules et leurs molecules chimeriques
WO2007144173A1 (fr) 2006-06-14 2007-12-21 Csl Behring Gmbh Protéine de fusion pouvant subir un clivage protéolytique et contenant un facteur de coagulation sanguine
EP2256135A1 (fr) 2006-06-14 2010-12-01 CSL Behring GmbH Protéine de fusion qui peut être clivée protéolyticalement et qui contient un facteur de la coagulation sanguine
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
KR101040486B1 (ko) 2008-08-25 2011-06-09 경북대학교 산학협력단 Ｐｄｋ4의 신규 용도
WO2011150241A2 (fr) 2010-05-28 2011-12-01 Genentech, Inc. Réduction du niveau de lactate et augmentation de la production de polypeptides par régulation négative de l'expression de la lactate déshydrogénase et de la pyruvate déshydrogénase kinase
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
US8765915B2 (en) 2006-02-06 2014-07-01 Csl Behring Gmbh Modified coagulation factor VIIa with extended half-life
EP2250251B1 (fr) 2008-01-09 2017-11-22 Sartorius Stedim Cellca GmbH Additif amélioré de milieu de culture et son procédé d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEBERNITZ GREGORY R ET AL: "Anilides of (R)-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase." JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 11, 1 June 2000 (2000-06-01), pages 2248-2257, XP001026040 ISSN: 0022-2623 cited in the application *
MURRAY K ET AL: "DICHLOROACETATE INCREASES CELL AND ANTIBODY YIELDS IN BATCH CULTURES OF A HYBRIDOMA CELL LINE" BIOTECHNOLOGY AND BIOENGINEERING. INCLUDING: SYMPOSIUM BIOTECHNOLOGY IN ENERGY PRODUCTION AND CONSERVATION, JOHN WILEY & SONS. NEW YORK, US, vol. 49, no. 4, 20 February 1996 (1996-02-20), pages 377-382, XP001022682 ISSN: 0006-3592 *
YOUNG P R ET AL: "SECRETION OF LACTIC ACID BY PERITONEAL MACROPHAGES DURING EXTRACELLULAR PHAGOCYTOSIS THE POSSIBLE ROLE OF LOCAL HYPERACIDITY IN INFLAMMATORY DEMYELINATION" JOURNAL OF NEUROIMMUNOLOGY, vol. 15, no. 3, 1987, pages 295-308, XP001022668 ISSN: 0165-5728 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006079155A1 (fr) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Molecules et leurs molecules chimeriques
US8765915B2 (en) 2006-02-06 2014-07-01 Csl Behring Gmbh Modified coagulation factor VIIa with extended half-life
WO2007144173A1 (fr) 2006-06-14 2007-12-21 Csl Behring Gmbh Protéine de fusion pouvant subir un clivage protéolytique et contenant un facteur de coagulation sanguine
EP2256135A1 (fr) 2006-06-14 2010-12-01 CSL Behring GmbH Protéine de fusion qui peut être clivée protéolyticalement et qui contient un facteur de la coagulation sanguine
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP3896090A1 (fr) 2006-06-14 2021-10-20 CSL Behring GmbH Protéine de fusion clivable par protéolyse comprenant un facteur de coagulation du sang
EP3564267A1 (fr) 2006-06-14 2019-11-06 CSL Behring GmbH Protéines de fusion clivable de manière protéolytique ayant une activité molaire spécifique élevée
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP2250251B1 (fr) 2008-01-09 2017-11-22 Sartorius Stedim Cellca GmbH Additif amélioré de milieu de culture et son procédé d'utilisation
KR101040486B1 (ko) 2008-08-25 2011-06-09 경북대학교 산학협력단 Ｐｄｋ4의 신규 용도
US9487809B2 (en) 2010-05-28 2016-11-08 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
EP2576580A4 (fr) * 2010-05-28 2014-07-02 Hoffmann La Roche Réduction du niveau de lactate et augmentation de la production de polypeptides par régulation négative de l'expression de la lactate déshydrogénase et de la pyruvate déshydrogénase kinase
KR20180069130A (ko) * 2010-05-28 2018-06-22 제넨테크, 인크. 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
US10011856B2 (en) 2010-05-28 2018-07-03 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
KR101869987B1 (ko) * 2010-05-28 2018-07-20 제넨테크, 인크. 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
KR101989762B1 (ko) 2010-05-28 2019-06-14 제넨테크, 인크. 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
KR20130077843A (ko) * 2010-05-28 2013-07-09 제넨테크, 인크. 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
US10704071B2 (en) 2010-05-28 2020-07-07 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
US11046987B2 (en) 2010-05-28 2021-06-29 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
WO2011150241A2 (fr) 2010-05-28 2011-12-01 Genentech, Inc. Réduction du niveau de lactate et augmentation de la production de polypeptides par régulation négative de l'expression de la lactate déshydrogénase et de la pyruvate déshydrogénase kinase

Also Published As

Publication number Publication date
AU2001275897A1 (en) 2002-01-21
WO2002004598A3 (fr) 2002-04-04

Similar Documents

Publication Publication Date Title
US7384765B1 (en) Cell culture performance with betaine
US6924124B1 (en) Feeding strategies for cell culture
US6974681B1 (en) Cell culture performance with vanadate
EP2152856B1 (fr) Milieux d'alimentation améliorés
JP5897708B2 (ja) 哺乳類細胞培養物
KR101362805B1 (ko) 개선된 세포 배양 배지
EP2601287B1 (fr) Dipeptides pour améliorer le rendement et la viabilité de cultures cellulaires
EP1497444B1 (fr) Procedes d'augmentation de la production de polypeptides
KR20140132017A (ko) 세포 배양의 개선
CN1296478C (zh) 细胞培养基
WO2002004598A2 (fr) Amelioration de performances de culture cellulaire
JP7495483B2 (ja) 濃縮灌流培地
US20040265964A1 (en) Inducers of recombinant protein expression
WO2008013809A1 (fr) Procédés de culture cellulaire
US8809049B2 (en) Methods for producing mammalian cells
CA2762016A1 (fr) Procedes d'augmentation de la production de polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载